These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 16359930)

  • 1. Pharmacogenetics: progress, pitfalls and clinical potential for coronary heart disease.
    Humphries SE; Hingorani A
    Vascul Pharmacol; 2006 Feb; 44(2):119-25. PubMed ID: 16359930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomics of cholesterol-lowering therapy.
    Schmitz G; Langmann T
    Vascul Pharmacol; 2006 Feb; 44(2):75-89. PubMed ID: 16337220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study.
    Donnelly LA; Doney AS; Dannfald J; Whitley AL; Lang CC; Morris AD; Donnan PT; Palmer CN
    Pharmacogenet Genomics; 2008 Dec; 18(12):1021-6. PubMed ID: 18815589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics: a molecular sophistication or a new clinical tool for cardiologists?
    Dirckx C; Donati MB; Iacoviello L
    Ital Heart J; 2000 Oct; 1(10):662-6. PubMed ID: 11061362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.
    Leey JA; McCabe S; Koch JA; Miles TP
    Am J Geriatr Pharmacother; 2009 Aug; 7(4):197-203. PubMed ID: 19766951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics of statin responsiveness.
    Kajinami K; Akao H; Polisecki E; Schaefer EJ
    Am J Cardiol; 2005 Nov; 96(9A):65K-70K; discussion 34K-35K. PubMed ID: 16291017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.
    Donnelly LA; Palmer CN; Whitley AL; Lang CC; Doney AS; Morris AD; Donnan PT
    Pharmacogenet Genomics; 2008 Apr; 18(4):279-87. PubMed ID: 18334912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction.
    Regieli JJ; Jukema JW; Grobbee DE; Kastelein JJ; Kuivenhoven JA; Zwinderman AH; van der Graaf Y; Bots ML; Doevendans PA
    Eur Heart J; 2008 Nov; 29(22):2792-9. PubMed ID: 18957472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of genetic variants associated with response to statin therapy.
    Mega JL; Morrow DA; Brown A; Cannon CP; Sabatine MS
    Arterioscler Thromb Vasc Biol; 2009 Sep; 29(9):1310-5. PubMed ID: 19667110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of pharmacogenetics in anticoagulation therapy.
    Hill CE; Duncan A
    Clin Lab Med; 2008 Dec; 28(4):513-24. PubMed ID: 19059059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical application of cardiovascular pharmacogenetics.
    Voora D; Ginsburg GS
    J Am Coll Cardiol; 2012 Jul; 60(1):9-20. PubMed ID: 22742397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological effects of lipid-lowering drugs recapitulate with a larger amplitude the phenotypic effects of common variants within their target genes.
    Knouff CW; Lim N; Song K; Yuan X; Walker MC; Townsend R; Waeber G; Matthews PM; Vollenweider P; Waterworth DM; Mooser V
    Pharmacogenet Genomics; 2008 Dec; 18(12):1051-7. PubMed ID: 18787507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Warfarin in the treatment of antiphospholipid syndrome].
    Reshetniak TM; Kondrat'eva LV; Patrusheva NL; Patrushev LI
    Ter Arkh; 2007; 79(5):47-54. PubMed ID: 17672075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic study of statin therapy and cholesterol reduction.
    Marian AJ
    Curr Atheroscler Rep; 2005 May; 7(3):177-8. PubMed ID: 15811249
    [No Abstract]   [Full Text] [Related]  

  • 16. Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy.
    Sabatine MS; Ploughman L; Simonsen KL; Iakoubova OA; Kirchgessner TG; Ranade K; Tsuchihashi Z; Zerba KE; Long DU; Tong CH; Packard CJ; Pfeffer MA; Devlin JJ; Shepherd J; Campos H; Sacks FM; Braunwald E
    Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):562-7. PubMed ID: 18174457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study.
    de Keyser CE; Eijgelsheim M; Hofman A; Sijbrands EJ; Maitland-van der Zee AH; van Duijn CM; Uitterlinden AG; Witteman JC; Ch Stricker BH
    Pharmacogenomics J; 2011 Feb; 11(1):72-80. PubMed ID: 20195290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins personalized.
    Superko HR; Momary KM; Li Y
    Med Clin North Am; 2012 Jan; 96(1):123-39. PubMed ID: 22391257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management.
    Kajinami K; Takekoshi N; Brousseau ME; Schaefer EJ
    Atherosclerosis; 2004 Dec; 177(2):219-34. PubMed ID: 15530894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic analysis of clinically relevant genetic polymorphisms.
    McLeod HL
    Clin Infect Dis; 2005 Nov; 41 Suppl 7():S449-52. PubMed ID: 16237646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.